$USPH
U S PHYSICAL THERAPY INC /NV

2021 Q1 Form 10-Q Financial Statement

#000114036121016561 Filed on May 10, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2020 Q1
Revenue $112.4M $112.7M
YoY Change -0.31% -3.02%
Cost Of Revenue $86.40M $93.30M
YoY Change -7.4% 4.25%
Gross Profit $25.90M $15.69M
YoY Change 65.04% -41.27%
Gross Profit Margin 23.05% 13.92%
Selling, General & Admin $10.87M $11.68M
YoY Change -6.88% 3.4%
% of Gross Profit 41.99% 74.42%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization $2.680M $2.610M
YoY Change 2.68% 8.75%
% of Gross Profit 10.35% 16.63%
Operating Expenses $10.87M $11.68M
YoY Change -6.88% 3.4%
Operating Profit $15.02M $4.014M
YoY Change 274.24% -73.98%
Interest Expense -$200.0K -$400.0K
YoY Change -50.0% 33.33%
% of Operating Profit -1.33% -9.97%
Other Income/Expense, Net -$192.0K -$384.0K
YoY Change -50.0%
Pretax Income $14.83M $3.630M
YoY Change 308.54% -75.93%
Income Tax $2.944M $292.0K
% Of Pretax Income 19.85% 8.04%
Net Earnings $8.173M $1.016M
YoY Change 704.43% -87.97%
Net Earnings / Revenue 7.27% 0.9%
Basic Earnings Per Share $0.21 $0.20
Diluted Earnings Per Share $0.21 $0.20
COMMON SHARES
Basic Shares Outstanding 12.87M 12.80M
Diluted Shares Outstanding 12.87M 12.80M

Balance Sheet

Concept 2021 Q1 2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $17.90M $89.60M
YoY Change -80.02% 343.56%
Cash & Equivalents $17.90M $89.55M
Short-Term Investments
Other Short-Term Assets $3.800M $4.822M
YoY Change -21.19% -7.27%
Inventory
Prepaid Expenses
Receivables $54.00M $42.65M
Other Receivables $0.00 $0.00
Total Short-Term Assets $75.80M $148.7M
YoY Change -49.02% 83.09%
LONG-TERM ASSETS
Property, Plant & Equipment $103.3M $22.98M
YoY Change 349.48% -76.79%
Goodwill $360.2M $330.8M
YoY Change 8.89%
Intangibles $57.59M $55.65M
YoY Change 3.5%
Long-Term Investments
YoY Change
Other Assets $1.500M $1.563M
YoY Change -4.03% 11.64%
Total Long-Term Assets $673.6M $445.7M
YoY Change 51.14% 0.86%
TOTAL ASSETS
Total Short-Term Assets $75.80M $148.7M
Total Long-Term Assets $673.6M $445.7M
Total Assets $749.4M $594.4M
YoY Change 26.09% 13.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $6.800M $3.000M
YoY Change 126.67% 57.89%
Accrued Expenses $51.67M $40.65M
YoY Change 27.13% -38.42%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $5.079M $728.0K
YoY Change 597.66% -33.82%
Total Short-Term Liabilities $90.80M $71.15M
YoY Change 27.62% 3.26%
LONG-TERM LIABILITIES
Long-Term Debt $16.57M $118.6M
YoY Change -86.03% 302.03%
Other Long-Term Liabilities $66.60M $380.0K
YoY Change 17426.32% -99.33%
Total Long-Term Liabilities $16.57M $380.0K
YoY Change 4260.79% -99.56%
TOTAL LIABILITIES
Total Short-Term Liabilities $90.80M $71.15M
Total Long-Term Liabilities $16.57M $380.0K
Total Liabilities $322.2M $260.5M
YoY Change 23.71% -14.13%
SHAREHOLDERS EQUITY
Retained Earnings $182.8M
YoY Change
Common Stock $151.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost) $31.63M
YoY Change
Treasury Stock Shares $2.215M
Shareholders Equity $276.2M $241.1M
YoY Change
Total Liabilities & Shareholders Equity $598.4M $643.3M
YoY Change -6.97% 22.97%

Cashflow Statement

Concept 2021 Q1 2020 Q1
OPERATING ACTIVITIES
Net Income $8.173M $1.016M
YoY Change 704.43% -87.97%
Depreciation, Depletion And Amortization $2.680M $2.610M
YoY Change 2.68% 8.75%
Cash From Operating Activities $17.67M $16.38M
YoY Change 7.88% 20.8%
INVESTING ACTIVITIES
Capital Expenditures -$1.610M -$2.750M
YoY Change -41.45% 10.0%
Acquisitions
YoY Change
Other Investing Activities -$11.60M -$13.17M
YoY Change -11.92% 518.31%
Cash From Investing Activities -$13.20M -$15.92M
YoY Change -17.09% 243.84%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -19.45M 65.55M
YoY Change -129.67% -643.53%
NET CHANGE
Cash From Operating Activities 17.67M 16.38M
Cash From Investing Activities -13.20M -15.92M
Cash From Financing Activities -19.45M 65.55M
Net Change In Cash -14.98M 66.01M
YoY Change -122.69% -2208.95%
FREE CASH FLOW
Cash From Operating Activities $17.67M $16.38M
Capital Expenditures -$1.610M -$2.750M
Free Cash Flow $19.28M $19.13M
YoY Change 0.78% 19.12%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2021Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2021Q1 dei Amendment Flag
AmendmentFlag
false
CY2021Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
CY2021Q1 dei Entity Central Index Key
EntityCentralIndexKey
0000885978
CY2021Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2021Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
CY2021Q1 dei Local Phone Number
LocalPhoneNumber
297-7000
CY2021Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2021Q1 dei Entity File Number
EntityFileNumber
1-11151
CY2021Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
76-0364866
CY2021Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
1300 WEST SAM HOUSTON PARKWAY SOUTH
CY2021Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
SUITE 300
CY2021Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
HOUSTON
CY2021Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77042
CY2021Q1 dei City Area Code
CityAreaCode
713
CY2021Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2021Q1 dei Document Period End Date
DocumentPeriodEndDate
2021-03-31
CY2021Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2021Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2021Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2021Q1 dei Trading Symbol
TradingSymbol
USPH
CY2021Q1 dei Security Exchange Name
SecurityExchangeName
NYSE
CY2021Q1 dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2021Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2021Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q1 dei Entity Shell Company
EntityShellCompany
false
CY2021Q1 dei Security12b Title
Security12bTitle
Common Stock, $.01 par value
CY2021Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12896572
CY2021Q1 us-gaap Goodwill
Goodwill
360176000
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
CY2021Q1 usph Accounts Payable Purchase Of Non Controlling Interest
AccountsPayablePurchaseOfNonControllingInterest
4828000
CY2020Q4 usph Accounts Payable Purchase Of Non Controlling Interest
AccountsPayablePurchaseOfNonControllingInterest
0
CY2021Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-192000
CY2020Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-384000
CY2021Q1 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
2453000
CY2020Q1 usph Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity
NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity
1796000
CY2021Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
1260000
CY2020Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
526000
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12870000
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12870000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12796000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12796000
CY2021Q1 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity
4829000
CY2020Q1 usph Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity
NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity
0
CY2021Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
287000
CY2020Q1 us-gaap Proceeds From Minority Shareholders
ProceedsFromMinorityShareholders
0
CY2021Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
4514000
CY2020Q1 us-gaap Dividends Payable Current And Noncurrent
DividendsPayableCurrentAndNoncurrent
4110000
CY2019 usph Number Of Regions
NumberOfRegions
6
CY2021Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4514000
CY2021Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
1672000
CY2021Q1 usph Short Swing Profit Settlement
ShortSwingProfitSettlement
14000
CY2019Q4 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
241701000
CY2020Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
1000
CY2020Q1 usph Revaluation Of Redeemable Non Controlling Interest Net Of Tax
RevaluationOfRedeemableNonControllingInterestNetOfTax
1570000
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1886000
CY2020Q1 usph Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans
TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans
487000
CY2020Q1 us-gaap Dividends Common Stock Cash
DividendsCommonStockCash
4110000
CY2020Q1 us-gaap Minority Interest Decrease From Distributions To Noncontrolling Interest Holders
MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
730000
CY2020Q1 us-gaap Stockholders Equity Other
StockholdersEquityOther
-43000
CY2020Q1 usph Net Income Loss Attributable To Noncontrolling Interest Permanent Equity
NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity
526000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1016000
CY2020Q1 us-gaap Stockholders Equity Including Portion Attributable To Noncontrolling Interest
StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
242304000
CY2021Q1 usph Average Physical Therapy Patients Volumes Per Day Per Clinic
AveragePhysicalTherapyPatientsVolumesPerDayPerClinic
27.1
CY2020Q1 usph Average Physical Therapy Patients Volumes Per Day Per Clinic
AveragePhysicalTherapyPatientsVolumesPerDayPerClinic
26.2
CY2021Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
2
CY2021Q1 usph Estimated Percentage Of Decrease In Payment
EstimatedPercentageOfDecreaseInPayment
0.035
CY2021Q1 usph Period Of Federal Debt Ceiling In Connection With Deficit Reductions
PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions
P10Y
CY2021Q1 usph Amount Of Reductions In Federal Spending
AmountOfReductionsInFederalSpending
1200000000000
CY2020 usph Number Of Regions
NumberOfRegions
6
CY2020 usph Number Of Regions
NumberOfRegions
6
CY2021Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
112368000
CY2020Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
112717000
CY2021Q1 usph Net Revenue From Medicare
NetRevenueFromMedicare
26600000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
1016000
CY2021Q1 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
-7270000
CY2020Q1 usph Charges To Retained Earnings Revaluation Of Non Controlling Interests
ChargesToRetainedEarningsRevaluationOfNonControllingInterests
2129000
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2555
CY2021Q1 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.2625
CY2021Q1 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
-1857000
CY2021Q1 usph Reduction In Medicare Spending Percentage
ReductionInMedicareSpendingPercentage
0.02
CY2013Q2 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2015Q4 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2018Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Expected Reduction In Medicare Spending Percentage
ExpectedReductionInMedicareSpendingPercentage
0.02
CY2021Q1 usph Percentage Of Increase In Payment Adjustment For Therapists Participating In Merit Based Incentive Payment System
PercentageOfIncreaseInPaymentAdjustmentForTherapistsParticipatingInMeritBasedIncentivePaymentSystem
0.01
CY2021Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2021Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2021Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2021Q1 usph Combined Physical Therapy Speech Language Pathology Expenses
CombinedPhysicalTherapySpeechLanguagePathologyExpenses
3700
CY2021Q1 usph Reduction In Combined Physical Therapy Speech Language Pathology Expenses
ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses
3000
CY2021Q1 usph Percentage Of Practice Expense Component Of Relative Value Unit
PercentageOfPracticeExpenseComponentOfRelativeValueUnit
1
CY2021Q1 usph Percentage Reduction For Service In Office Or Other Non Institutional Settings
PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings
0.50
CY2021Q1 usph Percentage Of Payment For Outpatient Therapy Services
PercentageOfPaymentForOutpatientTherapyServices
0.85
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
8173000
CY2020Q1 usph Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate
IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate
559000
CY2021Q1 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
2760000
CY2020Q1 usph Income Loss From Operations After Revaluation Of Non Controlling Interests
IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests
2586000
CY2021Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.21
CY2021Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.21
CY2020Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.20
CY2020Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.20
CY2021Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12870000
CY2021Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12870000
CY2020Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
12796000
CY2020Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12796000
CY2019Q4 us-gaap Goodwill
Goodwill
317676000
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
7812000
CY2021Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
368000
CY2021Q1 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
14416000
CY2020 us-gaap Goodwill Acquired During Period
GoodwillAcquiredDuringPeriod
28540000
CY2021Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1859000
CY2021Q1 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
114000
CY2020 us-gaap Goodwill Purchase Accounting Adjustments
GoodwillPurchaseAccountingAdjustments
1289000
CY2021Q1 us-gaap Goodwill
Goodwill
360176000
CY2020Q4 us-gaap Goodwill
Goodwill
345646000
CY2021Q1 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2363000
CY2020Q4 us-gaap Accrued Insurance Current
AccruedInsuranceCurrent
2113000
CY2020 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
1900000
CY2021Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
57593000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
56280000
CY2021Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
822000
CY2020Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
790000
CY2021Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24233000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
24646000
CY2021Q1 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
5822000
CY2020Q4 usph Patients And Payors Related Liability
PatientsAndPayorsRelatedLiability
5756000
CY2021Q1 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1042000
CY2020Q4 us-gaap Liabilities Of Disposal Group Including Discontinued Operation Current
LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent
1333000
CY2021Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
6371000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
5715000
CY2021Q1 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
0
CY2020Q4 usph Medicare Accelerated And Advance Payments Program Funds Payable
MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable
14054000
CY2021Q1 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
4170000
CY2020Q4 usph Deferred Employer Payroll Taxes Caresact
DeferredEmployerPayrollTaxesCARESACT
4170000
CY2021Q1 us-gaap Dividends Payable Current
DividendsPayableCurrent
4514000
CY2020Q4 us-gaap Dividends Payable Current
DividendsPayableCurrent
0
CY2021Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3156000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1959000
CY2021Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
51671000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
59746000
CY2020Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
294000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16596000
CY2021Q1 us-gaap Line Of Credit Facility Unused Capacity Commitment Fee Percentage
LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage
0.003
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5079000
CY2021Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
571000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
21650000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
21495000
CY2021Q1 us-gaap Long Term Debt Current
LongTermDebtCurrent
5079000
CY2020Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
4899000
CY2021Q1 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16571000
CY2021Q1 usph Long Term Debt Maturities Repayments Of Principal In Year Six
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearSix
16000000
CY2021Q1 us-gaap Long Term Debt
LongTermDebt
21650000
CY2021Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
7729000
CY2021Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1611000
CY2020Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1532000
CY2021Q1 us-gaap Lease Cost
LeaseCost
9708000
CY2020Q1 us-gaap Lease Cost
LeaseCost
9638000
CY2021Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
8112000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
7331000
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
7790000
CY2021Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
7867000
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
11540000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
22750000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
25637000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
19456000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
13006000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6732000
CY2021Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
94912000
CY2021Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5552000
CY2021Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
89360000
CY2021Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y3M18D
CY2021Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.030
CY2020Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.039
CY2021Q1 us-gaap Revenues
Revenues
112368000
CY2020Q1 us-gaap Revenues
Revenues
112717000
CY2021Q1 us-gaap Gross Profit
GrossProfit
25896000
CY2020Q1 us-gaap Gross Profit
GrossProfit
15691000
CY2021Q1 us-gaap Assets
Assets
598390000
CY2020Q1 us-gaap Assets
Assets
594361000
CY2021Q1 usph Short Swing Profit Settlement
ShortSwingProfitSettlement
12800
CY2008Q4 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
2250000
CY2009Q1 us-gaap Stock Repurchase Program Number Of Shares Authorized To Be Repurchased
StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
1200000
CY2009Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
859499
CY2021Q1 usph Additional Estimated Repurchase Of Common Stock
AdditionalEstimatedRepurchaseOfCommonStock
144092
CY2021Q1 us-gaap Shares Issued Price Per Share
SharesIssuedPricePerShare
104.10
CY2021Q1 us-gaap Stock Repurchased During Period Shares
StockRepurchasedDuringPeriodShares
0

Files In Submission

Name View Source Status
0001140361-21-016561-index-headers.html Edgar Link pending
0001140361-21-016561-index.html Edgar Link pending
0001140361-21-016561.txt Edgar Link pending
0001140361-21-016561-xbrl.zip Edgar Link pending
brhc10024114_10q.htm Edgar Link pending
brhc10024114_10q_htm.xml Edgar Link completed
brhc10024114_ex-32.htm Edgar Link pending
brhc10024114_ex31-1.htm Edgar Link pending
brhc10024114_ex31-2.htm Edgar Link pending
brhc10024114_ex31-3.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
usph-20210331.xsd Edgar Link pending
usph-20210331_cal.xml Edgar Link unprocessable
usph-20210331_def.xml Edgar Link unprocessable
usph-20210331_lab.xml Edgar Link unprocessable
usph-20210331_pre.xml Edgar Link unprocessable